Systemic lupus erythematosus (SLE) is a complex autoimmune condition, which often evolves with severe complications. In SLE, autoantibodies appear, with systemic inflammation and multiple tissue destructions. SLE is the most common form of lupus and is considered more severe than other forms. SLE can affect many parts of the body, including the kidneys, heart, lungs, brain, blood, and skin. Symptoms vary among patients. SLE can follow an unpredictable pattern of remissions (symptoms improve) and flares (symptoms worsen). Renal involvement is one of the most severe complications in SLE patients. The process of depositing the immune complexes in the kidneys could lead to the appearance of lupus nephritis. If the treatment is early and treat-to-target, it can change the course of the renal disease.
Osteoporosis is a systemic skeletal condition, characterized by a microarchitectural degradation of bone density and quality, giving low resistance and an increased risk of fracture. Osteoporosis is an important public health problem, with considerable medical, social and economic impact. Data accumulated in recent years demonstrate a significant incidence of osteoporosis in the group of patients with major collagen diseases; of these, Systemic Lupus Erythematosus (SLE) is the prototype of autoimmune disease in which osteoporosis and associated complications have a significant clinical impact. Although additional studies are needed to deepen the relationship between SLE - osteoporosis - associated fractures, we believe that these patients should be managed from the early stages of the disease.
Systemic lupus erythematosus is a multi-organ autoimmune disease of unknown etiology characterized by widespread inflammation and significant morbidity and mortality. Organ affection includes joint and cutaneous involvement, pulmonary, neurological, and cardiac problems, renal and hematological involvement as well as ocular comorbidities, both posterior but mostly anterior ocular involvement. Therefore, we aimed to evaluate dry eye involvement in lupus patients. A cross-sectional study was performed with the aid of a web-based, anonymous questionnaire that was distributed to both patients diagnosed with lupus erythematosus and to a control group. A total number of 123 patients diagnosed with lupus and 200 responders in the control group completed the questionnaire. Dry eye disease has already been diagnosed in 25 lupus patients (28.9%) compared to 44 (21.9%) individuals in the control group. Dry eye-related symptomatology was reported in 43 (34.60%) patients compared to 57 (28.35%) healthy responders. Upon statistical analysis, more symptoms were reported in the lupus group (p=0.01), in responders diagnosed with dry eye syndrome (p<0.01), and in responders using lubrication (p<0.01) but no association was obtained between the incidence of dry eye symptoms and the presence of the disease. The number of episodes of lupus reactivation since diagnosis was correlated with dry eye syndrome (p=0.15) and the use of lubricating tear drops (p<0.01). Dry eye symptoms and disease are more frequent in lupus patients and further research should be performed to understand the connection between these two disease entities.
